We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -7.79% | 3.55 | 3.50 | 3.60 | 3.85 | 3.55 | 3.85 | 888,756 | 16:01:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.35 | 3.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/1/2022 14:24 | Wulber - yes all good. I have added today, though might be a bit early as the market might punish further until the deal is signed. In the meantime I will stay away from all the nonsense here for the next few weeks until the inevitable rise back 70p Skol | ragnarr | |
05/1/2022 14:17 | Surely VAL have advisers who would shout up if they tried to do deals with a company who was not 100% legit and viable? | djj2014 | |
05/1/2022 14:17 | Francois if you feel so negative towards the company why not just sell up and move on? | sooty snipes | |
05/1/2022 14:07 | Thanks Ragnar, so all on track! | wulber | |
05/1/2022 14:06 | Anyone watched the wolf of Wall Street where di caprio is trying to sell penny stocks over the phone and he tells potential investor this company has a large Factory with state of the art facilities and then it pans out to the actual facilities and they are a garden shed in someone’s garden. Anyone getting the feeling Theormix are working from the same garden shed ….. | francoismyname | |
05/1/2022 14:02 | Great in the transcript she found time to laugh FFS whilst the share price tanks . | francoismyname | |
05/1/2022 13:48 | for the investors here is a transcript of Suzanne dilly interview answers. SD. Now this Service agreement is a really important step for us towards setting up the sub licence of VAL 201to TheormRx. So just tp provide a little bit of a recap just in case anyone listening here today hasn’t caught up on the news from the last couple of months from ValiRx Val 201 is our programme for Prostate cancer that we completed a clinical trial of last year, and we signed a letter of intent in November to say that we intend to sub licence VAL 201 for the use in Oncology, and just oncology, non-oncology uses stay with ValiRx, to a company called TheormRx. TheormRX are a newly incorporated company, incorporated in Delaware, in the US. This comprises a team of industry experts particularly including a patent agent Ken Sorenson who is frequently names in our RNS releases on the subject , who is executive chairman, but it also It also comprises chief scientists and a business operative. So we have been doing quite a lot of work with one of the scientists in particular since the letter of intent was signed in order to allow them to do due diligence on the programme, but also to start setting up the next clinical trial for VAL 201 which they will be sponsoring, be funding, but we are going to help them by providing some services via this consultancy agreement that enable us to make sure that our knowledge of the programme and our local knowledge, because they are hoping to run this trial in the UK, will be used to make sure this trial is set up promptly, and that it runs smoothly once it is up and running. So this next signature is exactly as we stated in the letter of intent announcement, but there are a number of documents that go along side the actual sub-licence that allow different things to happen around the deal. So, we also announced in December the first step of the progress towards the sub-licence when we announced that we had amended our licence with CRT, who we licenced the programme from initially, and now this licence allows us to start doing that work towards setting up the first trial. Now (laugh) it may not sound like very much, but because I have been going out with their scientists in order to talk to people who we are going to be sub-contracting the work to this means that I can be incorporated into the confidentiality agreements as consultant, and can go out physically on site to talk to people, visit hospitals in order to decide which clinics are going to be running the trial in. So, it really enables us to start running the trials process in parallel to their fund raise. Now clearly the sub-licence itself is subject to their successful fundraise, and when they have raised sufficient cash to run the trial, then we will be able to complete sub-licence signature, but in the meantime making sure everything is ready to go is a really important sept forwards. We have commented in the announcement that they expect to complete fundraising within Q1, we signed the Letter of intent in November and that really kicked off the their fund raising efforts, and that allowed them to go out to investors for the first time to show exactly what they had, what they were planning to develop, to do this fundraising. We announces at that time we were optimistic, that there was a chance for that funding to be completed by year end, clearly that has not happened, we are into the new year now, but we are very confident of it going ahead and we wouldn’t be putting the work into this service agreement if that wasn’t the case, and we have outlined the end of Q1 as a ..shall we say a long stop date in order to get the rest of the paperwork completed and for them to get their fund raising done, so we are working towards that, we are helping them to work towards that, and we are really positive for the future of this sub-licence | ragnarr | |
05/1/2022 13:27 | Don't be cruel.She works very hard to try and get this deal completed unfortunately US companies are the usual bs..ters | baldrick1 | |
05/1/2022 13:18 | I have £300 waiting for 7p lol | doerx2 | |
05/1/2022 13:06 | Anyone notice that whenever Suzy speaks the share price tanks. It’s like the market doesn’t believe a word she says. It was 3.5p down before the video and now 6.5p down. May be a message hidden there for Suzy to shut up . | francoismyname | |
05/1/2022 13:03 | I have now rid of my remaining holdings with a 30p average...not putting anymore cash until theorem has raised funds. | baldrick1 | |
05/1/2022 12:56 | It seems ridiculous that one financial times had forecasted this to drop to 6p.Theorem has to raise funds quickly otherwise that forecast would be inevitable): | baldrick1 | |
05/1/2022 12:41 | Above means getting funds in before new year for the avoidance of doubt | francoismyname | |
05/1/2022 11:25 | If you're right then I'll wait until it gets down to 22p before trebling my holdings so as to average my holdings to just 23p | baldrick1 | |
05/1/2022 09:29 | A bit difficult for Theorem to raise funds in the US at the moment best to put some of our money safe in UK banks like Lloyds. My number one choice with a target price of 62p+ | baldrick1 | |
05/1/2022 09:26 | Francois, in answer to your earlier question, I'm afraid to say you do. Try reading the RNS properly. Ridiculous reaction in my opinion | sooty snipes | |
05/1/2022 09:11 | Bought a few more for 32.2p | volsung | |
05/1/2022 08:56 | Good ole VAL always fails to deliver! | chesty1 | |
05/1/2022 08:56 | BOught a few back in after selling out in the recent spikes. nothing new here except a delay to signing the licence deal. All being well that happens in the next 2 months so rebought a few and may add if it drops a little more | dope007 | |
05/1/2022 08:47 | Good post on the other site FYI:Cebo-456 Premium MemberPosts: 1,400Price: 31.25No OpinionRE: SuzyToday 08:39It doesn't help that many muppets on here cannot read an RNS - this RNS is formalising the Service Agreement tjat was alluded to on the 02nd Nov RNS. This RNS states that the Company also believes everything is still on track and moving forward with TheoremRx with the sub licence deal - subject to TheoremRx completing their own fund raise.The reason there is no mention of the upfront payments on the RNS (as some have highlighted) is because that is part of the licensing deal, not this Service agreement. So despite what some wrote earlier - the "deal" for licensing Val201 hasn't been amended and the upfront payments will still be paid to Val.This RNS says that there is a slight delay in TheoremRx signing but all is still on track with the Licencing deal, it also says that other areas are progressing well and that T'Rx have now formally agreed to pay for Val advisory services going forward. Pretty sure Suzy will confirm this in an interview shortly. | wulber | |
05/1/2022 08:43 | Well said Carlisle, all moving along and moved on from LOI to Full Service Agreement. Stepping stones guys and good to see some chunky buying on an overdone dip. | wulber |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions